```html

Zollinger‑Ellison Syndrome (ZES) – Symptoms, Causes, Diagnosis and Treatment

What is Zollinger‑Ellison syndrome symptoms?

Zollinger‑Ellison syndrome (ZES) is a rare neuroendocrine disorder in which one or more gastrin‑producing tumors (gastrinomas) develop in the pancreas or the upper part of the small intestine (duodenum). These tumors secrete excessive amounts of the hormone gastrin, which in turn stimulates the stomach lining to produce large volumes of acid. The resulting hyperacidity leads to a characteristic pattern of gastrointestinal symptoms, most notably severe, recurring peptic ulcers.

Because the condition is uncommon (about 1–3 cases per million people per year) and its symptoms overlap with more common disorders such as peptic ulcer disease, it is often missed or diagnosed late. Understanding the specific symptom profile helps patients and clinicians recognize ZES sooner.

Common Causes

Zollinger‑Ellison syndrome itself is caused by gastrin‑secreting neuroendocrine tumors, but several underlying situations can be associated with its development or mimic its presentation:

• Gastrinomas – the primary cause; usually located in the duodenum (≈60 %) or pancreas.
• Multiple Endocrine Neoplasia type 1 (MEN‑1) – an inherited syndrome that predisposes to pancreatic neuroendocrine tumors, including gastrinomas.
• Genetic mutations in the MEN1 gene or APC gene that increase neuroendocrine tumor risk.
• Chronic Helicobacter pylori infection – can cause peptic ulcers that may be mistaken for ZES.
• Long‑term use of proton‑pump inhibitors (PPIs) – may mask ulcer symptoms and delay diagnosis.
• Other functional neuroendocrine tumors such as insulinomas or VIPomas that coexist with gastrinomas in MEN‑1.
• Familial pancreatic endocrine tumor syndromes – rare inherited conditions.
• Idiopathic hypergastrinemia – elevated gastrin without an identifiable tumor (very uncommon).
• Autoimmune gastritis – can cause high gastrin levels but usually leads to low acid, not the hyperacid state of ZES.
• Gastrectomy or gastric outlet obstruction – may cause secondary hypergastrinemia; symptoms differ but are sometimes confused with ZES.

Associated Symptoms

While the hallmark of ZES is excessive gastric acid, patients often experience a cluster of related complaints. The severity of symptoms can fluctuate with tumor size, number, and the amount of gastrin produced.

Gastrointestinal manifestations

• Recurrent, painful peptic ulcers – often multiple, larger than 2 cm, and located beyond the duodenum (e.g., jejunum, ileum).
• Severe epigastric burning pain – may worsen after meals or during the night.
• Chronic diarrhea – caused by acid inactivating pancreatic enzymes and damaging the intestinal mucosa.
• Steatorrhea (fatty stools) – malabsorption due to enzyme inactivation.
• Nausea and vomiting – sometimes with acid‑filled vomitus.
• Weight loss – secondary to malabsorption and poor appetite.
• Gastrointestinal bleed – melena or hematemesis from ulcer erosion.

Systemic signs

• Fatigue and anemia (iron‑deficiency) from chronic blood loss.
• Electrolyte disturbances (e.g., hypokalemia) secondary to prolonged diarrhea.
• Joint or bone pain – rare, may reflect metastatic disease.

When to See a Doctor

Because ZES can mimic ordinary heartburn or ulcer disease, vigilance is essential. Seek medical evaluation promptly if you experience any of the following:

• Recurrent ulcer pain that does not improve with standard ulcer therapy (e.g., PPIs, H2 blockers).
• Multiple ulcers identified on endoscopy, especially if they are >1 cm or located beyond the duodenum.
• Unexplained, persistent diarrhea (≥3 loose stools per day) together with abdominal pain.
• Sudden weight loss (>5 % of body weight over 3–6 months) without a clear cause.
• Vomiting that contains acid or looks like coffee grounds.
• Family history of MEN‑1, pancreatic neuroendocrine tumors, or multiple endocrine neoplasias.
• Any episode of gastrointestinal bleeding (black stools, bright red blood).

Diagnosis

Diagnosing ZES requires a combination of biochemical testing, imaging, and sometimes endoscopic evaluation. The goal is to confirm hypergastrinemia, demonstrate acid hypersecretion, and locate the gastrinoma.

Step‑by‑step diagnostic pathway

1. Fasting serum gastrin level – a level >1000 pg/mL (10 ng/mL) is highly suggestive, especially when the gastric pH is <2. Levels between 100–1000 pg/mL require further testing.
2. Secretin stimulation test – administration of secretin normally suppresses gastrin; paradoxical elevation (>120 pg/mL rise) supports ZES.
3. Gastric pH measurement – a pH <2 confirms acid hypersecretion.
4. Upper endoscopy (EGD) – visualizes ulcers and can obtain biopsies to rule out malignancy.
5. Imaging to locate the tumor:
   • Multiphasic contrast‑enhanced CT scan of the abdomen.
   • Magnetic resonance imaging (MRI) with gadolinium.
   • Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT, which are highly sensitive for neuroendocrine tumors.
6. Endoscopic ultrasound (EUS) – useful for small pancreatic lesions.
7. Genetic testing for MEN‑1 mutations when there is a family history or multiple endocrine tumors.

Reference: Mayo Clinic; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); WHO Classification of Tumors of the Digestive System.

Treatment Options

Management of ZES is aimed at controlling acid production, relieving symptoms, and removing or controlling the gastrinoma.

Medical therapy

• High‑dose proton‑pump inhibitors (PPIs) – the cornerstone of symptom control. Typical regimens start with omeprazole 60 mg/day or equivalent and are titrated to the lowest effective dose.
• H2‑receptor antagonists – may be added for breakthrough symptoms, though PPIs are usually sufficient.
• Somatostatin analogues (octreotide or lanreotide) – inhibit gastrin release; valuable when tumors are unresectable or metastatic.
• Antidiarrheal agents – loperamide for mild diarrhea; budesonide may help in severe cases.
• Vitamin and mineral supplementation – iron, calcium, vitamin D and B‑12 to address anemia and malabsorption.

Surgical options

• Curative resection – enucleation or pancreaticoduodenectomy (Whipple procedure) when the tumor is localized and resectable.
• Liver-directed therapies – for hepatic metastases (radiofrequency ablation, transarterial chemoembolization).
• Targeted systemic therapies – everolimus or sunitinib for advanced neuroendocrine tumors.

Home and lifestyle measures

• Take PPIs exactly as prescribed; do not abruptly stop without medical guidance.
• Avoid NSAIDs, aspirin, and other ulcer‑promoting drugs.
• Eat small, frequent meals; limit spicy, acidic, or fatty foods that may exacerbate symptoms.
• Stay hydrated—especially important if diarrhea is persistent.
• Maintain a symptom diary to help your clinician adjust therapy.

Prevention Tips

Because ZES is caused by tumor formation, primary prevention is limited. However, certain actions can reduce risk or aid early detection:

• Genetic counseling for families with known MEN‑1 mutations; early screening can identify gastrinomas before symptoms arise.
• Regular medical follow‑up for patients with known neuroendocrine tumors or MEN‑1.
• Avoid chronic use of ulcer‑aggravating medications (e.g., NSAIDs) unless medically necessary.
• Prompt evaluation of persistent abdominal pain or ulcers—early endoscopy can differentiate ordinary ulcer disease from ZES.
• Maintain a healthy weight and balanced diet to support overall gastrointestinal health.

Emergency Warning Signs

Summary

Zollinger‑Ellison syndrome is a rare but treatable cause of severe peptic ulcer disease and chronic diarrhea. Recognizing the pattern of recurrent, refractory ulcers, high gastrin levels, and excessive gastric acidity is essential for timely diagnosis. Laboratory testing, imaging, and, when appropriate, genetic evaluation guide management. High‑dose PPIs, surgery, and somatostatin analogues together control symptoms and address the underlying tumor. While the condition itself cannot be wholly prevented, awareness of family risk, avoidance of ulcer‑inducing drugs, and early medical evaluation of persistent gastrointestinal complaints can improve outcomes.

For personalized advice, always discuss symptoms and treatment options with a gastroenterologist or an endocrinologist familiar with neuroendocrine tumors.

```